Objective: To analyze the costs of human immunode ciency virus (HIV) outpatient treatment for individuals with di erent CD4 cell counts in the Brazilian public health system, and to compare to costs in other national health systems. Methods: A retrospective survey was conducted in ve public outpatient clinics of the Brazilian national HIV program in the city of São Paulo. Data on healthcare services provided for a period of one year of HIV outpatient treatment were gathered from randomly selected medical records. Prices of inputs used were obtained through market research and public sector databases. Information on costs of HIV outpatient treatment in other national health systems were gathered from the literature. Annual costs of HIV outpatient treatment from each country were converted into 2010 U.S. dollars.
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IntroductIon
Highly active antiretroviral therapy (HAART), adopted in 1996, combines antiretroviral drugs (ARVs) to reduce morbimortality rates among human immunodeficiency virus (HIV) patients, resulting in prolonged life expectancy [1] [2] [3] [4] [5] and increasing treatment costs.
Studies on costs of HIV treatment are usually performed through gross-costing techniques [6] [7] [8] [9] [10] [11] , analyzing specific healthcare expenditures [12] [13] [14] [15] [16] [17] [18] [19] , using private perspective [20] [21] [22] [23] [24] or exclusively using the costs for ARV provision [25] [26] [27] [28] [29] ; all of which report general trends of HIV treatment costs.
Although there is a general consensus on the considerable share of costs due to ARVs [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 30 , there is still lack of evidence on the major cost drivers of HIV outpatient treatment for individuals in different categories of CD4 cell count, particularly regarding nationwide publiclyfinanced HIV treatment programs, such as that of Brazil.
The Brazilian public program for HIV treatment was initiated in 1996 through ARVs distribution, prevention campaigns, and a healthcare program for sexually transmitted diseases (STD). In 2006, the program reached 180,000 individuals for HIV treatment within public health system. Currently, the Brazilian STD/ acquired immunodeficiency syndrome (AIDS) program provides inpatient and outpatient HIV treatment, including distribution of 17 HAART drugs 31, 32 .
According to Teixeira et al. 5 , the program resulted in decreased morbimortality and hospitalization rates; however, it also increased the demand for outpatient services and should continuously increase government expenditures due to the HIV incidence of approximately 20,000 cases per year 31, 32 .
Investigation on the cost composition of the Brazilian HIV program seems necessary to promote long-term public policy sustainability. Considering that usually there are data limitations to provide guidance for government decisions, this article seeks to offer evidence to contribute to strategic planning of public policies by analyzing the costs of HIV outpatient treatment for individuals with different CD4 cell counts within the Brazilian public program.
methodS

CharaCteriStiCS oF the BraziliaN StD/aiDS prograM
The analysis was based on a retrospective survey conducted in five public outpatient clinics in São Paulo, Brazil. The municipal branch of the Brazilian STD/AIDS program in São Paulo, known as the Programa Municipal DST/AIDS de São Paulo (PMDASP), consists of 15 clinics for outpatient treatment, three diagnostic facilities, and one administrative headquarters.
A micro-costing technique was used to perform costs estimates of HIV outpatient treatment for individuals with different CD4 cell counts within the program; based on identification, measurement, and valuation of resources required to provide the healthcare services demanded 33 , from the public provider perspective.
The Brazilian STD/AIDS program is considered a multiservice unit that provides HIV and STD outpatient treatments, HIV/STD diagnoses, and HIV/STD prevention activities. Therefore, the program requires sets of specific resources to provide healthcare services (healthcare-related inputs), and, additionally, a set of unspecific resources shared among several activities (technical-administrative inputs).
Implementation of the micro-costing technique to perform the analysis of costs derived from HIV outpatient treatment in the program encompassed three stages:
1. Identification and measurement of specific resources necessary to provide HIV outpatient treatment, through inventory of medical procedures performed in a sample of patients during 2006, in order to estimate the technical coefficients of the inputs; 2. Identification and measurement of unspecific resources necessary to support HIV outpatient treatment, via assessment of infrastructure and of the administrative sector within the program, and estimation of an overhead allocation factor; 3. Calculation of costs due to HIV outpatient treatment, through valuation of resources required using applicable prices and technical coefficients of inputs or overhead allocation factor, followed by addition of values and further data processing to account for inflation and exchange rates.
iNveNtory oF MeDiCal proCeDureS Sample
Sample size estimate was based on a population of 11,373 (67.7%) patients with CD4 cell count < 1,000 cells per µL at the beginning of the research in 2006, considering that CD4 cell count is usually adopted as a health status marker for HIV patients. A two-stage sampling process was performed in order to assure representativeness. In the first stage, five settings of the program were selected using a stratified purposive sampling method, in order to represent the variability of socio-demographic conditions in five different regions of São Paulo. Distribution of patients according to CD4 cell count within each of the 15 clinical settings was tested, in order to verify similarity in relation to the distribution of CD4 cell count in the program.
In the second stage, medical charts in each clinical setting were stratified according to CD4 cell count. A sample of 20 medical charts from each CD4 cell count stratum was randomly selected from each clinical setting; including a 30% projected rate of losses to follow-up due to abandonment of treatment, incomplete information, lost medical records, and other possible problems.
Discussion
In this study, the prevalence of traditional risk factors was similar to that previously found in other populations; for example, the 77.6% hypertension rate observed is compatible with the range from 46% to 82.5% reported in five other studies that included patients with atherosclerosis 10, 11, 16, 17, 20 . In the REACH Registry, where a total of 55.499 patients with symptomatic CAD, PAD or cerebrovascular disease from 44 different countries were analyzed, the authors found a prevalence of hypertension, hypercholesterolemia, diabetes, and smoking of 80%, 70.2%, 37.5%, and 14.4%, respectively 8 . These findings indicate the great potential of prevention practices in high-risk populations.
Although it is well recognized that lifestyle modification is one of the most important interventions for cardiovascular risk reduction, it is often neglected and less translated into clinical practice than medication prescription 9,10,20 .
In the present study, only 44.8% of the patients reported health procedures (e.g. therapy, counseling, medical consultation, curatives, and other) were collected through market research at retail suppliers. Prices related to dental services, diagnostics, and other exams were gathered from public databases on government fees for payment of private providers. Prices related to other inputs required (e.g. infant formula, condoms, and other) were obtained through market research at retail suppliers. Considering resources required for infrastructure/ administrative sector, prices of public utility services consumed during 2006 were based on total expenditures registered in the invoices. Expenditures on supporting services were gathered from the outsourcing contracts. Wages referring to human resources were obtained directly from the PMDASP payrolls. Prices of stationery and other office supplies were collected from the invoices.
Real estate was valued according to the opportunity cost of rental in the area occupied. Technical and administrative support equipment was valued according to market research conducted at retail suppliers. Obsolete equipment not found in market research was valued according to the inventory data from government accountancy systems provided by the Ministry of Health. Information on real estate and durable resource lifecycles was obtained from the Foundation Institute for Economic Research (Fundação Instituto de Pesquisas Econômicas -FIPE), which is responsible for cost of living estimates in São Paulo, in order to allow accounting for depreciation (corresponding to the amortization of the financial capital in each period, inversely related to resource lifecycle), maintenance (considered equivalent to depreciation), and daily opportunity costs due to financial operations in acquisition, using the official long-term interest rate for social programs from the Brazilian Development Bank (Banco Nacional de Desenvolvimento Econômico e Social -BNDES). Annual costs of HIV outpatient treatment from the Brazilian public program in São Paulo were stratified by CD4 cell count, considering major cost drivers according to categories. Literature research on studies analyzing the cost composition of HIV outpatient treatment in different international health systems was performed, in order to undertake a comparison across countries, considering only studies conducted through similar methodology and costing techniques. Patients with higher CD4 cell count had lower outpatient costs, accounting for nearly half of treatment costs estimated for patients with lower CD4 cell count. HIV outpatient treatment costs declined slightly for individuals with CD4 cell count ≤ 50 due to the decrease in ARV costs. Nevertheless, such shift in the structure of costs within the Brazilian public program is compensated by an increase in costs due to other healthcare services (such as dental care) within the program.
There were no significant differences in costs of HIV outpatient treatment in relation to individuals' gender and ethnicity. Regarding age group, average costs due to ARVs and exams were higher for younger individuals ( Table 2) .
Main cost drivers of HIV outpatient treatment in the Brazilian public program in São Paulo during 2006 were ARVs, medications other than ARV, health professional services, and diagnostic exams.
A significant proportion of HIV outpatient treatment costs was associated to ARV utilization, ranging from 55.8% of the annual outpatient treatment costs for individuals with CD4 cell count ≤ 50 to 66.8% of the annual outpatient treatment costs for individuals with 351 < CD4 ≤ 500.
Medications other than ARV represented 16.1% of the annual outpatient treatment costs for a typical HIV patient in the program, whereas the third cost category in terms of budgetary impact within the program was health professional services (8.7%). The proportion of costs due to medications other than ARVs presented broad variation across CD4 cell count strata, because of opportunistic illness treatment.
The shift in cost composition within the Brazilian public program for individuals with CD4 cell count ≤ 50 appears to be related to the lower consumption of health professional services in the case of patients in worst health condition. However, medications other than ARV take a higher priority among patients with CD4 cell count ≤ 50, probably due to opportunistic infections.
Literature research on HIV outpatient treatment costs for HAART retrieved seven studies reporting details of healthcare costs from different countries from the late 1990's until 2006-2007, based on micro-costing techniques using the public provider perspective 16, 17, [19] [20] [21] 30, 34 . One of the studies did not report ARV costs within HIV treatment 19 , and one study failed to present detailed data on HIV outpatient treatment costs 20 and therefore both were excluded from the cost composition comparison. Cost drivers of HIV outpatient treatment in different health systems presented a certain similarity regarding the share attributable to main cost categories (ARVs, medications other than ARV, health professional services, and exams). However, the cost composition of the Brazilian public program in São Paulo presented some differences in relation to other countries (Table 3) .
Additionally, the costs of HIV outpatient treatment in public programs 16, 21, 30, 34 were considerably lower compared to HIV outpatient treatment costs in private settings for the same period 17 . Costs from the Brazilian public program for HIV treatment in São Paulo during 2006 were equivalent to 10% to 20% of the costs reported in the USA study.
dIScuSSIon
The results obtained regarding cost composition of HIV outpatient treatment from the Brazilian public program in São Paulo during 2006 match those of the literature 16, 17, 21, 30, 34 , which indicate that the main cost drivers in HIV outpatient treatment are, correspondingly: ARVs, other medications, health professional services, and diagnostic exams. Nevertheless, the magnitude of cost drivers varied among HIV outpatient treatment programs due to health system efficiency, which may be associated with health financing structure and scale.
In terms of HIV program financing, the Brazilian public program for HIV treatment resembles the public financing scheme described in the Mexican study 16 , which provides publicly financed healthcare services for HIV outpatient treatment, while the treatment for HIV patients in the USA is usually based on private out-ofpocket expenditures.
ARVs still represented a major part of HIV outpatient treatment costs in the Brazilian public program, independently of CD4 cell count stratum. Although the Brazilian public program for HIV treatment is often discussed regarding ARV patents issues, a comparative study on ARV prices in Brazil and other low-to middleincome countries showed higher ARV prices in Brazil, especially in the case of locally-produced generic ARVs. Furthermore, the study shows that contrary to trends worldwide, generic ARVs prices have been increasing in Brazil since 2003 25 .
Considering that cost estimates may be subject to different methodologies, the cost comparison among healthcare services provided for HIV patients in different health systems was performed cautiously, in order to accomplish an adequate selection of studies that described in detail the costing techniques, estimation procedures, databases used, and perspective adopted.
According to Levy et al. 35 , less than 2% of country studies reporting costs of HIV treatment based on HAART provided "adequate data" or "useful estimates" to ensure "a meaningful statement about costs". Moreover, there are evidences of significant discrepancies between model estimates and country specialists' estimates on resource requirements for HIV care 36 .
Only five studies reporting details of HIV outpatient costs based on micro-costing techniques using public provider perspective were retrieved from the late 1990's to 2006-2007 16, 17, [19] [20] [21] 30, 34 . Other studies on HIV treatment costs were performed prior to HAART development, as properly summarized by Gebo et al. 17 . No study presenting more recent data on HIV treatment costs was retrieved. concluSIon Although cost comparison across different countries may be subject to some problems, due to both social context of the health system and methodology adopted for the cost estimates, this study aimed to illustrate the similarities and divergences in cost composition of HIV outpatient treatment provided in different national health systems, presenting the main costs drivers associated to various health financing arrangements. Public programs for universal HIV treatment, such as the Brazilian case, are widely recognized, but seldom analyzed in terms of economic costs. The few evidences available include government budgetary figures analysis through gross-costing technique 5, 31 or cost-effectiveness analysis based on ARV prescriptions at patient level 32 .
Additionally, the mortality rates due to HIV in São Paulo have been declining notably since the program was started in 1990's, decreasing from 21.2 to 7.9 deaths per 100,000 inhabitants during the period between 1991 and 2007, according to data from MonitorAIDS, a system from the Brazilian Ministry of Health designed to monitor the AIDS epidemics. The situation poses a challenge regarding strategies for public policy management in the health sector, in order to accomplish a balance between public financing through taxation and healthcare provision for the population.
The present study was designed to comprise a primary tool for public policy evaluation, and its results may be a valuable source of information for HIV programs worldwide. The main limitation of the analysis is the absence of cost estimates for HIV inpatient treatment. Additionally, the representativeness of the sample was calculated to characterize a municipal branch of the Brazilian public program for HIV treatment located in São Paulo and thus some results may not be extrapolated to country level due to scaling effects.
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